Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.71 |
| ▸ | CA2 | P00918 | 8/20 | 0.71 |
| ▸ | CA9 | Q16790 | 6/20 | 0.71 |
| ▸ | CA1 | P00915 | 6/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.71 |
| ▸ | CA12 | O43570 | 5/20 | 0.71 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7847235 | 1.00 | PTGS2 (0.71) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL18719790 | 0.85 | PTGS2 (0.73) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL5311683 | 0.83 | PTGS2 (1.00) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL5311687 | 0.83 | PTGS2 (1.00) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL18719785 | 0.83 | CA2 (0.71) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL5312314 | 0.83 | PTGS2 (1.00) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL18719797 | 0.83 | CA2 (0.57) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL5312313 | 0.83 | PTGS2 (1.00) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL5312322 | 0.83 | PTGS2 (0.70) | PTGS2CA2CA9CA1PTGS1 | |
| SCHEMBL5312325 | 0.83 | PTGS2 (0.70) | PTGS2CA2CA9CA1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1281709-B1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | URIACH Y COMPANIA S A J (ES) | 2005-02-16 | — | — | EP | disclosed |
| US-6838476-B1 | Cyclooxygenase inhibitors; anticancer agents | J. URIACH & CIA, SA (ES) | 2005-01-04 | — | — | US | disclosed |
| EP-1122243-B1 | NOVEL IMIDAZOLES WITH ANTI-INFLAMMATORY ACTIVITY | URIACH Y COMPANIA S A J (ES) | 2004-09-08 | — | — | EP | disclosed |
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | J. URIACH & CIA, S.A. (ES) | 2003-06-19 | — | — | US | disclosed |
| EP-1281709-A1 | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2003-02-05 | — | — | EP | disclosed |
| EP-1122243-A1 | NOVEL IMIDAZOLES WITH ANTI-INFLAMMATORY ACTIVITY | J. URIACH & CIA. S.A. (ES) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114456-A1 | Novel heterocylic compounds with anti-inflamatory activity | IL1B, IL1A, NFKBIA | PTGS2 23/4885CA2 1713/4885CA9 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.